[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646577":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":51,"responsibleParty":71,"collaborators":74,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":30,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":30,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Wageningen University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"A - Lean individuals (Low-glycemic breakfast)","EXPERIMENTAL","Lean participants randomized to consume a low-glycemic breakfast prior to administration of an oral \\[¹⁴C\\]-glucose microtracer to assess postprandial glucose metabolism.",[13],"Dietary Supplement: Low-glycemic breakfast (randomized vs high glycemic)",{"label":15,"type":10,"description":16,"interventionNames":17},"B - Lean individuals (High-glycemic breakfast)","Lean participants randomized to consume a high-glycemic breakfast prior to administration of an oral \\[¹⁴C\\]-glucose microtracer to assess postprandial glucose metabolism.",[18],"Dietary Supplement: High-glycaemic breakfast (randomized vs low glycemic)",{"label":20,"type":10,"description":21,"interventionNames":22},"C - Individuals with obesity (High-glycemic breakfast)","Participants with obesity consume a high-glycemic breakfast prior to administration of an oral \\[¹⁴C\\]-glucose microtracer to assess postprandial glucose metabolism.",[23],"Dietary Supplement: High-glycaemic breakfast",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Low-glycemic breakfast (randomized vs high glycemic)","Participants receive a single oral microtracer dose of \\[14C\\] glucose (≤10 kBq \u002F 270 nCi) mixed with 1 g unlabeled glucose, administered immediately after a low glycemic breakfast. The dose is prepared fresh on the morning of administration and consumed as a liquid drink. This approach enables tracing of glucose metabolism using Accelerator Mass Spectrometry (AMS) at extremely low radiation exposure (\\~0.006 mSv). The intervention is combined with indirect calorimetry, serial blood sampling (including arterialized and deep-venous lines), expired air collection for 14CO₂ recovery, and pooled urine\u002Ffeces collection over 72 hours to quantify metabolic fate and pathway activity.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"High-glycaemic breakfast (randomized vs low glycemic)","Participants receive a single oral microtracer dose of \\[14C\\] glucose (≤10 kBq \u002F 270 nCi) mixed with 1 g unlabeled glucose, administered immediately after a high glycemic breakfast. The dose is prepared fresh on the morning of administration and consumed as a liquid drink. This approach enables tracing of glucose metabolism using Accelerator Mass Spectrometry (AMS) at extremely low radiation exposure (\\~0.006 mSv). The intervention is combined with indirect calorimetry, serial blood sampling (including arterialized and deep-venous lines), expired air collection for 14CO₂ recovery, and pooled urine\u002Ffeces collection over 72 hours to quantify metabolic fate and pathway activity.",[15],{"type":26,"name":36,"description":33,"armGroupLabels":37,"otherNames":30},"High-glycaemic breakfast",[20],[39],{"name":40,"affiliation":5,"role":41},"Marlou Dirks, PhD","PRINCIPAL_INVESTIGATOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","+31 317-484 136","Marlou.Dirks@wur.nl",{"name":48,"role":44,"phone":49,"phoneExt":30,"email":50},"Ayesha Heinis, PhD","+31 6-21578392","ayesha.heinis@wur.nl",[52],{"facility":53,"status":54,"city":55,"state":30,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Wageningen University and Research","RECRUITING","Wageningen","6708 WD","Netherlands","NL",{"type":60,"coordinates":61},"Point",[62,63],5.66667,51.97,{"lat":63,"lon":62},[66,68],{"name":48,"role":44,"phone":67,"phoneExt":30,"email":50},"0621578392",{"name":40,"role":44,"phone":69,"phoneExt":30,"email":70},"0031317-484 136","marlou.dirks@wur.nl",{"type":41,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Marlou Dirks","Prinicipal Investigator",[75,78],{"name":76,"class":77},"Bonumose, Inc.","UNKNOWN",{"name":79,"class":6},"TNO","100646577","how-the-body-processes-sugar-after-eating-in-people-with-different-body-weights-100646577",false,"NCT07690176","How the Body Processes Sugar After Eating, in People With Different Body Weights","The Metabolic Effects of a Hyperglycaemic Meal in Lean and Obese Individuals Using a [14C]-Glucose Microtracer Approach","Inclusion Criteria:\n\n* Healthy males and females using contraception during and for 3 months after the study.\n* Aged from 18-65 years at the time of signing informed consent\n* 18.5 \\\u003C BMI \\\u003C 25 kg·m2 or 30\\\u003C BMI \\\u003C35 kg·m2\n* Must be willing and able to communicate and participate in the whole study, including consumption of 14C-glucose and meals offered during study conduct\n* Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)\n* Must usually eat 3 meals per day (i.e. breakfast, lunch and dinner)\n\nExclusion Criteria:\n\n* Diabetes (Type 1, Type 2, or genetic form of diabetes)\n* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and\u002For ≥90 mmHg diastolic)\n* HbA1c higher than 53 mmol\u002Fmol\n* History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastro-intestinal disease, immunodeficiency, endocrine, neurological, or psychiatric disorders\n* Any diagnosed respiratory disease, such as COPD or asthma\n* Any previous motor disorders or disorders in muscle and\u002For lipid metabolism\n* Known severe kidney problems\n* Presence of an ulcer in the stomach or gut and\u002For strong history of indigestion\n* Recent or chronic history of diarrhoea\n* Known anaemia\n* A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia.\n* Regular use of dietary supplements (\\>3 times per week)\n* Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)\n* History of any drug or alcohol abuse in the past two years\n* A confirmed positive alcohol breath test at screening or admission\n* Drug use\n* Claustrophobia\n* Subjects who are on a weight loss diet or following a high calorific\u002Fhigh protein diet to gain weight\n* Subjects with functional constipation\n* Any known food allergies or intolerances to the 14 major food allergens (celery, cereals containing gluten, crustaceans, eggs, fish, lupin, milk, molluscs, mustard, tree nuts, peanuts, sesame seeds, soybeans, sulphur dioxide and sulphites) or history of a malabsorption syndrome including coeliac disease\n* Subjects who have regular gastrointestinal complaints including abdominal pain, stomach upsets and borborygmi or known or suspected irritable bowel syndrome\n* Currently taking part in another scientific research\n* Having received a product with 14C in the past 12 months\n* Pregnant or breastfeeding\n* Smoking or having used nicotine-containing products in the 6 months prior to the study.\n* Subjects who have taken antibiotics within the 60 days prior to the adaptation period.\n* Currently involved in a structured progressive resistance training programme (\\>3 times per week)\n* Sedentary lifestyle as assessed using the International Physical Activity Questionnaire \\[IPAQ\\].\n* Unable to give consent\n* Employed or undertaking a thesis or internship at the department of Human and Animal Physiology",true,"ALL","18 Years","65 Years",{"count":92,"type":93},24,"ESTIMATED","INTERVENTIONAL",[96],"NA","The goal of this clinical trial is to learn how a high-glycaemic meal affects the way the body processes glucose in healthy adults who are either lean or have obesity. The main questions it aims to answer are: Is the polyol pathway (conversion of glucose into sorbitol and fructose) more active after a hyperglycaemic meal? Is this pathway more active in individuals with obesity compared with lean individuals? We will compare people who eat a high-glycaemic meal with those who eat a low-glycaemic meal to see whether meal type changes how glucose is metabolized in the body. Participants will drink a small amount of 14C-labelled glucose so researchers can trace how the body uses glucose, spend one long study day (about 12 hours in the lab) plus short morning visits on days 2 to 4, and undergo repeated measurements, including blood sampling, breath sampling, indirect calorimetry, and complete urine and stool collection for 72 hours. This information will help us understand how glucose is processed in the body and whether people with obesity handle glucose differently than lean individuals.",[99],"Obesity & Overweight",[101,102,103,104,105,106,107],"Hyperglycaemic meal","14C-glucose","microtracer","accelerator mass spectrometry","polyol pathway","de novo lipogenesis","arteriovenous forearm balance","2026-07-01",{"date":110,"type":111},"2026-07-08","ACTUAL",{"date":113,"type":111},"2026-02-24",{"date":115,"type":93},"2026-07-30",{"name":5,"class":6},1]